When is Lugol still necessary in 2020?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Screening for second primary tumors in the aerodigestive tract in non-Asian populations with head and neck cancer - systematic review and meta-analysis.ESMO gastrointestinal oncology · 2025
   Review
2. Screening for synchronous esophageal second primary tumors in patients with head and neck cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021
   Article
3. Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: a nationwide study in a Western population.United European gastroenterology journal · 2021
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.